Clinical Trials Logo

Clinical Trial Summary

SevEos is a cross-sectional, multi-center, non-interventional study aimed to describe the treatment patterns in 250 severe asthma patients across the Gulf region. In addition, the study will determine the current level of asthma control and quality of life in these patients; describe the exacerbation patterns; and determine the current levels of blood eosinophils for the enrolled patients.


Clinical Trial Description

The primary objective of this study is to describe the treatments patterns of severe asthmatic patients across four Gulf countries during the past year.

Secondary Objectives

1. To determine the current level of asthma control in these patients. In addition, a comparison of uncontrolled asthma between those with a eosinophilic count ≥ 300 cell/μl and those with an elevated eosinophilic count less than that.

2. To determine the current and past year levels of blood eosinophils, and the percentage of patients with elevated eosinophilic level ≥ 150 cells/μL and ≥ 300 cells/μL

3. To describe the frequency of exacerbations during the past year.

4. To assess the current quality of life (QoL) of these patients.

5. To determine the past year levels of serum IgE.

6. Exploratory objective: To determine the past year levels of other inflammatory biomarkers like periostin and fraction of exhaled nitric oxide (FeNO). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03387722
Study type Observational
Source AstraZeneca
Contact
Status Completed
Phase
Start date December 31, 2017
Completion date January 3, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma Phase 2
Recruiting NCT05472324 - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. Phase 2
Recruiting NCT04914078 - Severe Asthma Exacerbations and Mepolizumab Treatment
Completed NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects Phase 1
Recruiting NCT04520165 - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Not yet recruiting NCT04463836 - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Enrolling by invitation NCT06421402 - K-HEALTH in AIR - Barcelona Pilot - Cohort
Recruiting NCT03377920 - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's. N/A
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Recruiting NCT04045587 - International Severe Asthma Registry: Canadian Cohort
Completed NCT05616338 - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC) N/A
Active, not recruiting NCT02038374 - Clinico-biological Correlation of Severe Asthma in Children N/A
Active, not recruiting NCT02114034 - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting NCT06035289 - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting NCT03532685 - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up N/A
Completed NCT03931954 - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting NCT03984253 - Swiss Severe Asthma Register
Recruiting NCT03435237 - Phenotyping Asthma for Bronchial Thermoplasty
Recruiting NCT03476109 - Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. Phase 4